Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro.

Literature DB >> 26883697

Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro.

Hannelore I Bax¹, Irma A J M Bakker-Woudenberg², Marian T Ten Kate², Annelies Verbon³, Jurriaan E M de Steenwinkel².

Abstract

Thein vitroactivities of clarithromycin and tigecycline alone and in combination againstMycobacterium aviumwere assessed. The activity of clarithromycin was time dependent, highly variable, and often resulted in clarithromycin resistance. Tigecycline showed concentration-dependent activity, and mycobacterial killing could only be achieved at high concentrations. Tigecycline enhanced clarithromycin activity againstM. aviumand prevented clarithromycin resistance. Whether there is clinical usefulness of tigecycline in the treatment ofM. aviuminfections needs further study.

Entities: Chemical Species

Mesh：

Substances：

Year: 2016 PMID： 26883697 PMCID： PMC4808172 DOI： 10.1128/AAC.02864-15

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

15 in total

Review 1. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence.

Authors: Jakko van Ingen; Beatriz E Ferro; Wouter Hoefsloot; Martin J Boeree; Dick van Soolingen
Journal: Expert Rev Anti Infect Ther Date: 2013-10 Impact factor: 5.091

Review 2. The pharmacokinetic and pharmacodynamic profile of tigecycline.

Authors: Alison K Meagher; Paul G Ambrose; Thaddeus H Grasela; Evelyn J Ellis-Grosse
Journal: Clin Infect Dis Date: 2005-09-01 Impact factor: 9.079

3. Simplified, accurate method for antibiotic assay of clinical specimens.

Authors: J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal: Appl Microbiol Date: 1966-03

4. Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: clinical features and susceptibilities of the isolates.

Authors: Meng-Rui Lee; Jen-Chung Ko; Sheng-Kai Liang; Shih-Wei Lee; David Hung-Tsang Yen; Po-Ren Hsueh
Journal: Int J Antimicrob Agents Date: 2014-03-20 Impact factor: 5.283

5. Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages.

Authors: Lawrence H Bopp; Aldona L Baltch; William J Ritz; Phyllis B Michelsen; Raymond P Smith
Journal: Diagn Microbiol Infect Dis Date: 2011-01 Impact factor: 2.803

6. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.

Authors: Jurriaan E M de Steenwinkel; Gerjo J de Knegt; Marian T ten Kate; Alex van Belkum; Henri A Verbrugh; Kristin Kremer; Dick van Soolingen; Irma A J M Bakker-Woudenberg
Journal: J Antimicrob Chemother Date: 2010-10-14 Impact factor: 5.790

7. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors: Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal: Antimicrob Agents Chemother Date: 2002-10 Impact factor: 5.191

8. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.

Authors: Chien-Wen Huang; Jiann-Hwa Chen; Shiau-Ting Hu; Wei-Chang Huang; Yen-Chung Lee; Chen-Cheng Huang; Gwan-Han Shen
Journal: Int J Antimicrob Agents Date: 2013-01-09 Impact factor: 5.283

Review 9. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature.

Authors: A P Garrison; M I Morris; S Doblecki Lewis; L Smith; T J Cleary; G W Procop; V Vincek; I Rosa-Cunha; B Alfonso; G W Burke; A Tzakis; A I Hartstein
Journal: Transpl Infect Dis Date: 2009-08-10 Impact factor: 2.228

10. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.

Authors: Jurriaan E M de Steenwinkel; Marian T ten Kate; Gerjo J de Knegt; Kristin Kremer; Rob E Aarnoutse; Martin J Boeree; Henri A Verbrugh; Dick van Soolingen; Irma A J M Bakker-Woudenberg
Journal: Emerg Infect Dis Date: 2012-04 Impact factor: 6.883

5 in total

Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro.

Review 1. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence.

Review 2. The pharmacokinetic and pharmacodynamic profile of tigecycline.

3. Simplified, accurate method for antibiotic assay of clinical specimens.

4. Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: clinical features and susceptibilities of the isolates.

5. Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages.

6. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.

7. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

8. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.

Review 9. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature.

10. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.

1. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.

2. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.

3. Drug Susceptibility of 33 Reference Strains of Slowly Growing Mycobacteria to 19 Antimicrobial Agents.

Review 4. MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections.

5. Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV.